IsoPSA Test
Prostate-specific antigen (PSA) is a widely used biomarker for prostate cancer detection, aiding early diagnosis and timely intervention. While serum total PSA levels above 4 ng/mL indicate increased prostate cancer risk and levels above 10 ng/mL are strongly suggestive of malignancy, traditional PSA testing lacks specificity for prostate cancer. Elevated PSA levels can also be seen in benign prostatic hyperplasia (BPH) and other non-malignant prostate conditions, leading to unnecessary prostate biopsies, increasing patient morbidity, risk of infection, and healthcare costs.
Unlike conventional concentration-based PSA assays, IsoPSA is a structure-based test that evaluates variations in PSA molecular composition. Using a solvent interaction analysis with an aqueous two-phase reagent system, IsoPSA partitions PSA into different isoforms, allowing for more accurate risk stratification. This approach helps distinguish between benign/low-grade prostate cancer and high-grade prostate cancer, providing superior specificity. Clinical studies indicate that IsoPSA reduces the need for prostate biopsies by approximately 60%, significantly improving patient management. The test performance is independent of total PSA concentration, making it a valuable adjunct in prostate cancer screening.
Patients over 50 years old with total PSA >4 ng/mL are recommended for IsoPSA testing to guide biopsy decisions.
- Identifies patients at high risk of clinically significant prostate cancer
- Aids in reducing unnecessary prostate biopsies
- Provides greater specificity in differentiating benign conditions from aggressive prostate cancer
IsoPSA Index Score Interpretation:
- Low Risk: Unlikely to have clinically significant prostate cancer (Gleason Score <7).
- Intermediate Risk: Further clinical correlation needed; biopsy may be considered.
- High Risk: Likely to have clinically significant prostate cancer (Gleason Score ≥7), biopsy recommended.
Results are based on fractional isoform composition analysis and should be correlated with clinical findings, imaging, and digital rectal exam (DRE).
IsoPSA Index values are interpreted within clinical context; no universal cut-off exists
Whole blood (EDTA tube).
Stability
- Ambient: unacceptable
- Refrigerated: 24 hours
- Frozen: 14 days
- Urol Oncol. 2022 Sep;40(9):408.e9-408.e18. [PMID: 35840465]
- Eur Urol. 2017 Dec;72(6):942-949. [PMID: 28396176]
- Urol Pract. 2022 Mar;9(2):173-180. [PMID: 37145695]
- J Urol. 2019 Jun;201(6):1115-1120. [PMID: 30810464]
- Nat Rev Clin Oncol. 2020 Jun;17(6):372-381. [PMID: 32112055]